



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

July 15, 2021

David Southwell  
Chief Executive Officer  
TScan Therapeutics, Inc.  
830 Winter Street  
Waltham, MA 02451

**Re: TScan Therapeutics, Inc.**  
**Form S-1**  
**Exhibit Nos. 10.5, 10.7, 10.8 and 10.9**  
**Filed April 23, 2021**  
**File No. 333-255491**

Dear Mr. Southwell:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance